Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose escalation and expansion of PF-06821497 (EZH2 inhibitor) in Japanese adults with castration-resistant prostate cancer
jRCT2031230184Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of mevrometostat in prostate cancer (PCa), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities and maximum tolerated dose, Overall safety profile (adverse events) and 3 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031230184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230184.